Paper7601015
Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.
Balfour JA and 2 others. Drugs, 1995. Cited by 16 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections. Papers, record 7601015. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7601015
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bacterial Infections | Major topic |
| Fleroxacin | Major topic |
| Animals | |
| Bacteria | |
| Clinical Trials as Topic | |
| Drug Interactions | |
| Humans | |
| Microbial Sensitivity Tests |
Source PubMed
References231
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 2,920,479 | The pharmacokinetics and tissue penetration of the fluoroquinolones. | Clin Invest Med | 1989 | https://conductscience.org/library/papers/2920479 | PubMed |
| 2 | 8,452,165 | Fleroxacin versus norfloxacin in the treatment of urinary tract infections: a multicenter, double-blind, prospective, randomized, comparative study. | Am J Med | 1993 | https://conductscience.org/library/papers/8452165 | PubMed |
| 3 | 3,264,554 | Antibiotic susceptibilities and plasmid profiles of Haemophilus ducreyi isolates from southern Africa. | J Antimicrob Chemother | 1988 | https://conductscience.org/library/papers/3264554 | PubMed |
| 4 | 3,119,553 | Fleroxacin (Ro 23-6240): activity in vitro against 355 enteropathogenic and non-fermentative gram-negative bacilli and Legionella pneumophila. | J Antimicrob Chemother | 1987 | https://conductscience.org/library/papers/3119553 | PubMed |
| 5 | 1,909,831 | [Bacteriological and clinical studies on fleroxacin in male gonococcal urethritis]. | Hinyokika Kiyo | 1991 | https://conductscience.org/library/papers/1909831 | PubMed |
| 6 | 10,146,890 | Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections. | Pharmacoeconomics | 1993 | https://conductscience.org/library/papers/10146890 | PubMed |
| 7 | 7,689,444 | Quinolones in sexually transmitted diseases. | Drugs | 1993 | https://conductscience.org/library/papers/7689444 | PubMed |
| 8 | 2,569,597 | Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. | Lancet | 1989 | https://conductscience.org/library/papers/2569597 | PubMed |
| 9 | 8,385,956 | The withdrawal of temafloxacin. Are there implications for other quinolones? | Drug Saf | 1993 | https://conductscience.org/library/papers/8385956 | PubMed |
| 10 | 2,849,604 | In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone. | J Antimicrob Chemother | 1988 | https://conductscience.org/library/papers/2849604 | PubMed |
| 11 | 2,116,256 | Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. | Clin Pharmacokinet | 1990 | https://conductscience.org/library/papers/2116256 | PubMed |
| 12 | 2,129,330 | High-performance liquid chromatographic assay and erythrocyte partitioning of fleroxacin, a new fluoroquinolone antibiotic. | J Pharm Biomed Anal | 1990 | https://conductscience.org/library/papers/2129330 | PubMed |
| 13 | 2,511,802 | Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin. | Antimicrob Agents Chemother | 1989 | https://conductscience.org/library/papers/2511802 | PubMed |
| 14 | 1,693,968 | Conditions required for the bactericidal activity of fleroxacin and pefloxacin against Escherichia coli KL 16. | J Med Microbiol | 1990 | https://conductscience.org/library/papers/1693968 | PubMed |
| 15 | 8,463,172 | Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. | J Antimicrob Chemother | 1993 | https://conductscience.org/library/papers/8463172 | PubMed |
| 16 | 7,927,833 | Bacterial resistance to fluoroquinolones: lessons to be learned. | Infection | 1994 | https://conductscience.org/library/papers/7927833 | PubMed |
| 17 | 3,144,539 | Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers. | J Antimicrob Chemother | 1988 | https://conductscience.org/library/papers/3144539 | PubMed |
| 18 | 3,144,534 | Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. | J Antimicrob Chemother | 1988 | https://conductscience.org/library/papers/3144534 | PubMed |
| 19 | 1,482,143 | Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers. | Antimicrob Agents Chemother | 1992 | https://conductscience.org/library/papers/1482143 | PubMed |
| 20 | 2,114,419 | Determination of the new fluoroquinolone fleroxacin and its N-demethyl and N-oxide metabolites in plasma and urine by high-performance liquid chromatography with fluorescence detection. | J Chromatogr | 1990 | https://conductscience.org/library/papers/2114419 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 35,631,484 | Metal(II) Complexes of the Fluoroquinolone Fleroxacin: Synthesis, Characterization and Biological Profile. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/35631484 | PubMed |
| 34,452,252 | Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones-Shaping the Fifth Generation. | Pharmaceutics | 2021 | https://conductscience.org/library/papers/34452252 | PubMed |
| 12,908,854 | Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine. | Clin Pharmacokinet | 2003 | https://conductscience.org/library/papers/12908854 | PubMed |
| 9,757,930 | In vitro activity of fleroxacin against multiresistant gram-negative bacilli isolated from patients with nosocomial infections. | Intensive Care Med | 1998 | https://conductscience.org/library/papers/9757930 | PubMed |
| 9,433,651 | Effect of age and gender on the pharmacokinetics of grepafloxacin. | Clin Pharmacokinet | 1997 | https://conductscience.org/library/papers/9433651 | PubMed |
| 8,799,689 | Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. | Drugs | 1996 | https://conductscience.org/library/papers/8799689 | PubMed |
| 8,741,236 | Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections. | Drugs | 1996 | https://conductscience.org/library/papers/8741236 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7601015
GET https://conductscience.org/api/papers/v1/7601015/references?page=2